A One-Year Partial Double-Blinded, Randomized, Multi-Center, Multi-National Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis.
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Zoledronic acid (Primary) ; Teriparatide
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Novartis
- 23 Mar 2011 Status changed from active, no longer recruiting to completed.
- 01 Mar 2011 Results published in the Journal of Bone and Mineral Research.
- 21 Oct 2009 Results were reported at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.